230313-75-4

Upstream product

• 64471-47-2 (R)-α-phenyl-α-cyclopentyl-α-hydroxyacetate methyl ester 
• 137-43-9 Cyclopentyl bromide 
• 90581-53-6 (2S,5S)-2,5-diphenyl-1,3-dioxolan-4-one 
• 860644-55-9 (-)-2'-cyclopentyl-2'-phenyl-2'-hydroxyacetic acid [N-(2,2,2-trichloroethoxyformyl)-3-aza-bicyclo[3.3.1]nonan-9-yl]ester (+)-N-p-tosylglutamic acid salt 
• 895153-68-1 3-azabicyclo[3,3,1]nonan-9-yl 2'-cyclopentyl-2'-hydroxy-2'-phenylacetate 
• 611-71-2 (R)-Mandelic Acid 
• 17199-29-0 (S)-Mandelic acid 
• 64471-45-0 (2R)-2-cyclopentyl-2-hydroxy-2-phenylacetic acid 

Relevant academic research and scientific papers

Simultaneous enantioselective determination of seven psychoactive drugs enantiomers in multi-specie animal tissues with chiral liquid chromatography coupled with tandem mass spectrometry

In stock farming, illegal use of antipsychotics has caused the food safety problem. This paper presents for the first time, a multi-residues method for the simultaneous enantioselective determination of seven antipsychotics in pork, beef and lamb muscles. The behaviors of Chiralpak AGP toward changes in pH and organic modifier in mobile phase were studied, and all analytes were rapidly separated within 30 min. The calibration curves of all enantiomers were linear in the range of 1–250 ng g?1, with correlation coefficient above 0.9931. The recoveries of the targeted compounds were higher than 82.1%, with repeatability and intermediate precision lower than 18.2% and 17.4%, respectively. In three matrices, the limit of detection and limit of quantification ranged from 0.20 to 0.65 ng g?1 and from 0.40 to 1.00 ng g?1, respectively. The proposed method can be used to provide additional information for the reliable risk assessment of chiral antipsychotics.

SELECTIVE M4 RECEPTOR ANTAGONIST AND ITS MEDICAL USE

The present invention provides a selective M4 receptor antagonist, levorotatory demethylated phencynonate or its nontoxic pharmaceutically acceptable salt, a pharmaceutical composition comprising this compound, and a use thereof in the manufacture of a medicament for the treatment of motion dysfunction, such as, tremor, rigor and the like caused by Parkinson's disease (PD). The structure of the compound is shown in Formula IIa:

Optical resolution, stereoselective synthesis, and crystal structure of 9α-(3-azabicyclo[3,3,1]nonanyl)-2′cyclopentyl-2′-hydroxy- 2′-phenylacetate

9α-(3-Azabicyclo[3,3,1 ]nonanyl)-2′-cyclopentyl-2′- hydroxy-2′-phenylacetate (1) was synthesized and its enantiomers were obtained by the optical resolution of racemates with the chiral host N-p-toluenesulfonylglutamic acid. Optical pure 1 was also effect